Chloroquine as a prophylactic agent against COVID-19?

Mathieu Gendrot, Emilie Javelle, Axelle Clerc, Hélène Savini, Bruno Pradines, Mathieu Gendrot, Emilie Javelle, Axelle Clerc, Hélène Savini, Bruno Pradines

Abstract

  1. •

    Efficacy of chloroquine and hydroxychloroquine in COVID-19 treatment is discussed.

  2. •

    Prophylactic use of chloroquine or hydroxychloroquine in COVID-19 is considered.

References

    1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCov) in vitro. Cell Res. 2020;30:269–271.
    1. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 Mar 9 doi: 10.1093/cid/ciaa237. pii: ciaa237.
    1. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30:297–308.
    1. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Mar 10 doi: 10.1016/j.jcrc.2020.03.005. pii: S0883-9441(20)30390-7.
    1. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi: 10.5582/bst.2020.01047.
    1. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177 doi: 10.1016/j.antiviral.2020.104762.
    1. Multicenter collaboration group of Department of Science and Technology of Guandong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:185–188. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009.
    1. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20 doi: 10.1016/j.ijantimicag.2020.105949.
    1. Iannetta M, Ippolito G, Nicastri E. Azithromycin shows anti-Zika virus activity in human glial cells. Antimicrob Agents Chemother. 2017;61 doi: 10.1128/AAC.01152-17. e01152–17.
    1. Li C, Zu S, Deng YQ, Li D, Parvatiyar K, Quanquin N. Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses. Antimicrob Agents Chemother. 2019;63(12) doi: 10.1128/AAC.00394-19. e00394–19.
    1. Pagès F, Boutin JP, Meynard JB, Keundjian A, Ryfer S, Giurato L. Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria prophylaxis. Trop Med Int Healh. 2002;7:919–924.
    1. Michel R, Bardot S, Queyriaux B, Boutin JP, Touze JE. Doxycycline-chloroquine vs. doxycycline placebo for malaria prophylaxis in nonimmune soldiers: a double-blind randomized field trial in sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2010;104:290–297. doi: 10.1016/j.trstmh.2009.10.001.
    1. Peragallo MS, Sabatinelli G, Sarnicola G. Compliance and tolerability of mefloquine and chloroquine and chloroquine plus proguanil for long-term malaria prophylaxis in groups at particular risk (the military) Trans R Soc Trop Med Hyg. 1999;93:73–77.
    1. World Health Organization Advances in malaria chemotherapy. Report of a WHO scientific group. 1990
    1. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996;31:257–274.
    1. Zhou P, Huang Z, Xiao Y, Huang X, Fan XG. Protecting Chinese healthcare workers while combating the 2019 novel Coronavirus. Infect Control Hosp Epidemiol. 2020;5:1–4. doi: 10.1017/ice.2020.60.
    1. Taylor WRJ, White NJ. Antimalarial drug toxicity. Drug Saf. 2004;27:25–61.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir